Poor
Mostly Aligned
Patient Risk:
Low
Summary
Most extracted claims are not supported by the provided label excerpts; several are likely incorrect relative to what the supplied label text contains (notably osteoarthritis/rheumatoid arthritis indications, which are not present in the provided Indications section).
Category Scores
Accurate Statements
Meloxicam is an active pharmaceutical ingredient used in medications.
Label excerpt 11 DESCRIPTION describes XIFYRM (meloxicam injection) and meloxicam as the active pharmaceutical ingredient.
Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID).
Label excerpt 11 DESCRIPTION: “XIFYRM (meloxicam injection) is a nonsteroidal anti-inflammatory drug (NSAID).”
Unsupported Statements
Meloxicam medications are typically formulated with inactive ingredients to create the final dosage form.
No information about inactive ingredients/formulation generalities is provided in the supplied label excerpts.
The specific inactive ingredients in meloxicam can vary by manufacturer and formulation.
No statement about variability of inactive ingredients across manufacturers/formulations is present in the supplied label excerpts.
Meloxicam tablets commonly include binders, fillers, disintegrants, lubricants, and colorants.
The supplied label excerpts do not describe tablet excipients or functional categories.
Microcrystalline cellulose is commonly used as a binder or filler in meloxicam tablets.
No excipient list for tablets (or microcrystalline cellulose) is provided in the supplied label excerpts.
Lactose monohydrate is commonly used as a binder or filler in meloxicam tablets.
No excipient list for tablets (or lactose monohydrate) is provided in the supplied label excerpts.
Crospovidone is commonly used as a disintegrant in meloxicam tablets.
No excipient list for tablets (or crospovidone) is provided in the supplied label excerpts.
Magnesium stearate is commonly used as a lubricant to prevent sticking during manufacturing of meloxicam tablets.
No excipient list for tablets (or magnesium stearate) is provided in the supplied label excerpts.
Titanium dioxide is commonly used as a colorant in meloxicam medications.
No colorant/excipient information for meloxicam tablets is provided in the supplied label excerpts.
Iron oxides may be included as colorants for identification and appearance in meloxicam medications.
No colorant/excipient information for meloxicam products is provided in the supplied label excerpts.
Meloxicam is available in oral tablets, capsules, and oral suspensions.
The supplied label excerpt is for XIFYRM (meloxicam injection) only; no dosage-form availability for oral tablets/capsules/suspensions is provided.
Meloxicam works by blocking the production of certain chemicals in the body that cause inflammation.
The label excerpt 12.1 describes inhibition of cyclooxygenase (COX-1 and COX-2) and decreased prostaglandins; the claim is a generalized paraphrase and is not directly supported as stated.
Patent expiration for meloxicam can involve patents on the active ingredient and on specific formulations or manufacturing processes.
Not addressed in the supplied FDA label excerpts.
DrugPatentWatch.com tracks information on meloxicam market exclusivity end dates.
Not addressed in the supplied FDA label excerpts.
Contradictions
Low
AI Statement
Meloxicam is used to relieve pain and inflammation associated with osteoarthritis.
Label Reference
1 INDICATIONS AND USAGE (provided excerpt): XIFYRM indicated for management of moderate-to-severe pain in adults; no osteoarthritis indication stated in the provided excerpt.
Low
AI Statement
Meloxicam is used to relieve pain and inflammation associated with rheumatoid arthritis.
Label Reference
1 INDICATIONS AND USAGE (provided excerpt): XIFYRM indicated for management of moderate-to-severe pain in adults; no rheumatoid arthritis indication stated in the provided excerpt.
Important Omissions
Any label-supported dosing/administration details for XIFYRM (meloxicam injection) (e.g., dose, frequency, maximum dose, administration instructions) were not included in the extracted claim set.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated claims are largely about excipients/dosage forms and mechanism at a high level; however, two indication claims (osteoarthritis and rheumatoid arthritis) conflict with the provided label indication excerpt for XIFYRM (management of moderate-to-severe pain). No contraindications/boxed warnings specific claims were made in the extracted set, so safety-related omissions cannot be fully assessed from the provided excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Indication claims (osteoarthritis/rheumatoid arthritis) conflict with the supplied label excerpt (XIFYRM indicated for moderate-to-severe pain in adults). Many excipient/tablet formulation and dosage-form availability assertions are unsupported by the provided label excerpts.
Suggested Improvement
Restrict claims to what is explicitly present in the provided labeling: (1) use the label’s stated indication for XIFYRM (moderate-to-severe pain in adults) and its limitation of use; (2) avoid making tablet excipient and oral dosage-form availability claims unless the specific label sections (e.g., inactive ingredients/how supplied) are provided.